Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Evaluation of a New Interface Combining High-Flow Nasal Cannula and CPAP.

Garofalo E, Bruni A, Pelaia C, Cammarota G, Murabito P, Biamonte E, Abdalla K, Longhini F, Navalesi P.

Respir Care. 2019 Jun 4. pii: respcare.06871. doi: 10.4187/respcare.06871. [Epub ahead of print]

PMID:
31164484
2.

Single Inhaler LABA/LAMA for COPD.

Malerba M, Foci V, Patrucco F, Pochetti P, Nardin M, Pelaia C, Radaeli A.

Front Pharmacol. 2019 Apr 25;10:390. doi: 10.3389/fphar.2019.00390. eCollection 2019.

3.

Patient-ventilator asynchrony in adult critically ill patients.

Bruni A, Garofalo E, Pelaia C, Messina A, Cammarota G, Murabito P, Corrado S, Vetrugno L, Longhini F, Navalesi P.

Minerva Anestesiol. 2019 Jun;85(6):676-688. doi: 10.23736/S0375-9393.19.13436-0. Epub 2019 Feb 13.

PMID:
30762325
4.

Rapid Detection and Identification of Antimicrobial Peptide Fingerprints of Nasal Fluid by Mesoporous Silica Particles and MALDI-TOF/TOF Mass Spectrometry: From the Analytical Approach to the Diagnostic Applicability in Precision Medicine.

Preianò M, Maggisano G, Murfuni MS, Villella C, Colica C, Fregola A, Pelaia C, Lombardo N, Pelaia G, Savino R, Terracciano R.

Int J Mol Sci. 2018 Dec 12;19(12). pii: E4005. doi: 10.3390/ijms19124005.

5.

Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.

Pelaia C, Calabrese C, Barbuto S, Busceti MT, Preianò M, Gallelli L, Savino R, Vatrella A, Pelaia G.

Pulm Pharmacol Ther. 2019 Feb;54:25-30. doi: 10.1016/j.pupt.2018.11.002. Epub 2018 Nov 7.

PMID:
30414440
6.

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness.

Pelaia C, Calabrese C, Terracciano R, de Blasio F, Vatrella A, Pelaia G.

Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618810192. doi: 10.1177/1753466618810192. Review.

7.

Fluid Challenge During Anesthesia: A Systematic Review and Meta-analysis.

Messina A, Pelaia C, Bruni A, Garofalo E, Bonicolini E, Longhini F, Dellara E, Saderi L, Romagnoli S, Sotgiu G, Cecconi M, Navalesi P.

Anesth Analg. 2018 Dec;127(6):1353-1364. doi: 10.1213/ANE.0000000000003834.

PMID:
30300177
8.

Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.

Pelaia C, Busceti MT, Solinas S, Terracciano R, Pelaia G.

Pulm Pharmacol Ther. 2018 Dec;53:1-5. doi: 10.1016/j.pupt.2018.09.006. Epub 2018 Sep 11.

PMID:
30217438
9.

Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.

Pelaia C, Calabrese C, Vatrella A, Busceti MT, Garofalo E, Lombardo N, Terracciano R, Pelaia G.

Biomed Res Int. 2018 May 10;2018:4839230. doi: 10.1155/2018/4839230. eCollection 2018. Review.

10.

Recognizing, quantifying and managing patient-ventilator asynchrony in invasive and noninvasive ventilation.

Garofalo E, Bruni A, Pelaia C, Liparota L, Lombardo N, Longhini F, Navalesi P.

Expert Rev Respir Med. 2018 Jul;12(7):557-567. doi: 10.1080/17476348.2018.1480941. Epub 2018 May 31. Review.

PMID:
29792537
11.

Maxillary sinus mucocele with orbital complications.

Lombardo N, Ferrise P, Piazzetta GL, Bruzzichessi D, Testa D, Viola P, Pelaia C, Motta G.

Ann Ital Chir. 2018 Apr 9;7. pii: S2239253X18028190.

PMID:
29661986
12.

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.

Pelaia C, Vatrella A, Bruni A, Terracciano R, Pelaia G.

Drug Des Devel Ther. 2018 Mar 21;12:619-628. doi: 10.2147/DDDT.S155307. eCollection 2018. Review.

13.

An Analytical Method for Assessing Optimal Storage Conditions of Gingival Crevicular Fluid and Disclosing a Peptide Biomarker Signature of Gingivitis by MALDI-TOF MS.

Preianò M, Maggisano G, Murfuni MS, Villella C, Pelaia C, Montalcini T, Lombardo N, Pelaia G, Savino R, Terracciano R.

Proteomics Clin Appl. 2018 Sep;12(5):e1800005. doi: 10.1002/prca.201800005. Epub 2018 Apr 23.

PMID:
29603653
14.

Mechanical ventilation in brain injured patients: seeing the forest for the trees.

Bruni A, Garofalo E, Pelaia C, Longhini F, Navalesi P.

J Thorac Dis. 2017 Oct;9(10):3483-3487. doi: 10.21037/jtd.2017.08.149. No abstract available.

15.

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.

Pelaia C, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Savino R, Pelaia G.

Drug Des Devel Ther. 2017 Oct 30;11:3137-3144. doi: 10.2147/DDDT.S150656. eCollection 2017. Review.

16.

Biological mechanisms underlying the clinical effects of allergen-specific immunotherapy in asthmatic children.

Pelaia C, Vatrella A, Lombardo N, Terracciano R, Navalesi P, Savino R, Pelaia G.

Expert Opin Biol Ther. 2018 Feb;18(2):197-204. doi: 10.1080/14712598.2018.1402003. Epub 2017 Nov 8. Review.

PMID:
29113525
17.

Dupilumab for the treatment of asthma.

Pelaia C, Vatrella A, Gallelli L, Terracciano R, Navalesi P, Maselli R, Pelaia G.

Expert Opin Biol Ther. 2017 Dec;17(12):1565-1572. doi: 10.1080/14712598.2017.1387245. Epub 2017 Oct 8. Review.

PMID:
28990423
18.

Long-term treatment in pediatric asthma: an update on chemical pharmacotherapy.

Vitale C, Maglio A, Pelaia C, Vatrella A.

Expert Opin Pharmacother. 2017 May;18(7):667-676. doi: 10.1080/14656566.2017.1317747. Epub 2017 Apr 20. Review.

PMID:
28387160

Supplemental Content

Loading ...
Support Center